<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[biotechnology company Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/biotechnology+company.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to biotechnology company]]></description>
	<s:counts start="0" returned="11" found="11" />
	<language>en-us</language>
	<item>
		<title><![CDATA[How To Value A Biotechnology Company]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=953551]]></link>
		<description><![CDATA[The major risk to be quantified in the valuation of a biotechnology company is the risk of successfully completing clinical trials. In order to accurately asses the value of a biotech company, it is crucial to have an understanding of the clinical development process for human therapeutics - the costs,...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Thu, 01 Jan 2009 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/risk.html"><![CDATA[Risk]]></category>
		<category domain="http://resources.bnet.com/topic/deloitte+llp.html"><![CDATA[Deloitte LLP]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[Biotechnology Company]]></category>
		<category domain="http://resources.bnet.com/topic/clinical+trial.html"><![CDATA[Clinical Trial]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
	</item>
	<item>
		<title><![CDATA[Sequenom Misses, but Who Cares?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F103120-sequenom-misses-but-who-cares%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Trader Mark submits: Near term results for Sequenom SQNM are really a moot point as we're looking to mid 2009 forward on this story; the main issue in this new and not so improved environment is making sure young companies have cash to get them to the point where they...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 30 Oct 2008 07:11:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/trader.html"><![CDATA[Trader]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[Biotechnology Company]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/trader+mark.html"><![CDATA[Trader Mark]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/trader+mark.html"><![CDATA[Trader Mark]]></category>
		<category domain="http://resources.bnet.com/topic/sequenom+inc..html"><![CDATA[Sequenom Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SQNM</category>
		<category domain="tickers">SQNM</category>
	</item>
	<item>
		<title><![CDATA[WuXi PharmaTech Q3 2007 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-13071_23-231777.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Your first question comes from Jinsong Du - Credit Suisse.  Jinsong Du  - Credit Suisse  Congratulations on the results. You mentioned in the slides that you now have 80 clients. I remember during the IPO road show that it was at 70. I understand...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 13 Nov 2007 20:46:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[Biotechnology Company]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/credit+suisse+group+ag.html"><![CDATA[Credit Suisse Group AG]]></category>
		<category domain="http://resources.bnet.com/topic/customer.html"><![CDATA[Customer]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/general+electric+co..html"><![CDATA[General Electric Co.]]></category>
		<category domain="http://resources.bnet.com/topic/j.p.+morgan+chase+%2526+co..html"><![CDATA[J.P. Morgan Chase & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JPM</category>
		<category domain="tickers">GE,JPM</category>
	</item>
	<item>
		<title><![CDATA[Protesters undermine French GM research.(biotechnology company Monsanto have condemned the destruction of two experimental maize plots)(Brief article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6680/is_200608/ai_n26429172]]></link>
		<description><![CDATA[A French farmers' union and the biotechnology company Monsanto  have condemned the destruction of two experimental maize plots in  central France and another in eastern France last Sunday night,  Terre-Net reports.    A French farmers' union and the biotechnology company Monsanto  have condemned the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 18 Aug 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[biotechnology company]]></category>
		<category domain="http://resources.bnet.com/topic/general+motors+corp..html"><![CDATA[General Motors Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/monsanto.html"><![CDATA[Monsanto]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GMGMQ</category>
		<category domain="tickers">GMGMQ</category>
	</item>
	<item>
		<title><![CDATA[CAMBRIDGE ANTIBODY TECHNOLOGY (CAT).]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb6602/is_200602/ai_n26019561]]></link>
		<description><![CDATA[678p - Pharmaceuticals - Cambridge Antibody Technology CAT stands  out among the UK's biotechnology companies for one big reason: it  is the first British biotech company to have a blockbuster product on  the market. Humira, the company's antibody dru  678p - Pharmaceuticals - Cambridge Antibody Technology...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 24 Feb 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/abbott+laboratories+inc..html"><![CDATA[Abbott Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[biotechnology company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
		<category domain="tickers">ABT</category>
	</item>
	<item>
		<title><![CDATA[Verity PharmaCI: Using Information to Stay Ahead of the Competition in Life Sciences]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=150066]]></link>
		<description><![CDATA[Pharmaceutical and biotechnology companies are under pressure to bring drugs to market quicker. Thus there is a need to maximize their return on each new drug introduced to the market, to comply with stringent government regulations, to understand the impact of patent expiration on their drug portfolio and to rapidly...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Wed, 29 Jun 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/verity+inc..html"><![CDATA[Verity Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[Biotechnology Company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/life+science.html"><![CDATA[Life Science]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
	</item>
	<item>
		<title><![CDATA[The Drug Industry's Alliance Archipelago]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=149205]]></link>
		<description><![CDATA[Big pharmaceuticals have the money to fund the development and marketing of new drugs, but their R&D hit rate has not been sufficient to replace products coming off patent. Small biotechnology companies are awash in new technologies, but lack the cash to bring products through the expensive regulatory approval processes....]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Mon, 01 Dec 2003 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/accenture+ltd..html"><![CDATA[Accenture Ltd.]]></category>
		<category domain="http://resources.bnet.com/topic/alliance.html"><![CDATA[Alliance]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[Biotechnology Company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACN</category>
		<category domain="tickers">ACN</category>
	</item>
	<item>
		<title><![CDATA[Can You Capture & Value The Price Of Speed?: Outsourcing For Drug Development & Manufacturing]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=69868]]></link>
		<description><![CDATA[Outsourcing drug research has become more popular, not only because of increased efficiencies in third-party core competencies, but also because numerous Pharmaceutical & Biotech companies are often challenged with conflicting budgets, dated equipment, software or knowledge that may or may not fall short of existing regulatory allowances. Emphasis has traditionally...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Wed, 01 Jan 2003 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[Biotechnology Company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/outsourcing.html"><![CDATA[Outsourcing]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
	</item>
	<item>
		<title><![CDATA[Local biotech firms flower during May.(securities, finance)(Brief Article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5253/is_200106/ai_n20185655]]></link>
		<description><![CDATA[Local biotech companies got a lift during May as investors rewarded  signs of progress in new products.    After it announced its second consecutive profitable quarter and a  medical journal endorsed a product it makes for breast cancer treatment,  Down  Local biotech companies got...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 11 Jun 2001 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[biotechnology company]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[finance]]></category>
		<category domain="http://resources.bnet.com/topic/molex+inc..html"><![CDATA[Molex Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[security]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[stock]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MOLX</category>
		<category domain="tickers">MOLX</category>
	</item>
	<item>
		<title><![CDATA[A New Approach to Valuing Biotech Stocks]]></title>
		<link><![CDATA[http://jobfunctions.bnet.com/abstract.aspx?docid=104392]]></link>
		<description><![CDATA[Stocks of biotechnology companies are soaring. However, while these companies have promising technologies, they are years away from profits. The boomlet shows, however, how hard it is to value biotech stocks. Analysts often use proxy drivers such as the number of patents or the dollar value of partnerships to value...]]></description>
		<s:doctype><![CDATA[White papers]]></s:doctype>
		<pubDate>Sun, 11 Feb 2001 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/university+of+pennsylvania.html"><![CDATA[University Of Pennsylvania]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[Biotechnology Company]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
	</item>
	<item>
		<title><![CDATA[Biotech Companies Question FDA Regulation Proposals.(Knight Ridder/Tribune Business News)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5553/is_200101/ai_n22500998]]></link>
		<description><![CDATA[Jan. 31--Biotechnology companies planning to conduct gene therapy  and animal-to-human transplants are questioning new regulations that  require them to provide more details about their tests and immediate  public notification of side effects.    Jan. 31--Biotechnology companies planning to conduct gene therapy  and animal-to-human transplants...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 30 Jan 2001 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+company.html"><![CDATA[Biotechnology company]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
